<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1006932.ref033">
 <label>33</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Agnandji</surname>
   <given-names>ST</given-names>
  </name>, 
  <name>
   <surname>Fernandes</surname>
   <given-names>JF</given-names>
  </name>, 
  <name>
   <surname>Bache</surname>
   <given-names>EB</given-names>
  </name>, 
  <name>
   <surname>Obiang Mba</surname>
   <given-names>RM</given-names>
  </name>, 
  <name>
   <surname>Brosnahan</surname>
   <given-names>JS</given-names>
  </name>, 
  <name>
   <surname>Kabwende</surname>
   <given-names>L</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: A phase I randomised trial</article-title>. 
  <source>PLoS Med</source>. 
  <year>2017</year>;
  <volume>14</volume>(
  <issue>10</issue>):
  <fpage>e1002402</fpage>
  <comment>doi: 
   <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1002402" xmlns:xlink="http://www.w3.org/1999/xlink">10.1371/journal.pmed.1002402</ext-link>
  </comment> ; PubMed Central PMCID: PMCPMC5630143.
  <?supplied-pmid 28985239?>
  <pub-id pub-id-type="pmid">28985239</pub-id>
 </mixed-citation>
</ref>
